Clinical trials: Leukemia, Lymphoblastic
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth.
- Trial name
- Benefit VA (NCT06520098)
- Testing
- Venetoclax, Ibrutinib, Acalabrutinib, Zanubrutinib
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- VA Office of Research and Development
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one…
- Trial name
- BRUIN CLL-322 (NCT04965493)
- Testing
- Pirtobrutinib, Venetoclax, Rituximab
- Where
- 176 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- Loxo Oncology, Inc.
Leukemia, Lymphoma
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00004084
- Testing
- indium In 111 LL2 IgG, yttrium Y 90 epratuzumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Leukemia, Acute Lymphoblastic
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system…
- Trial name
- NCT04307576
- Testing
- Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy
- Where
- 137 sites in Belgium, Denmark and 13 more
- Volunteers
- 6,430 people
- Sponsor
- Mats Heyman
Leukemia, Lymphoma
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus.
- Conditions
- Leukemia, Lymphoma, Precancerous Condition, Small Intestine Cancer
- Trial name
- NCT00006340
- Testing
- arginine butyrate, ganciclovir
- Where
- 6 sites in United States, France and 2 more
- Sponsor
- Boston Medical Center
Myeloproliferative Disorders, Leukemia
Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
RATIONALE: Antiemetic drugs, such as aprepitant and ondansetron, may help lessen nausea and vomiting caused by opioids. It is not yet known whether aprepitant is more effective than ondansetron in treating nausea and vomiting…
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00499668
- Testing
- aprepitant, ondansetron hydrochloride
- Sponsor
- Vanderbilt-Ingram Cancer Center
Neoplasms, Cancer
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
The Cancer Experience Registry®: An Online Survey Research Study to Understand the Experiences of Those Impacted By a Cancer Diagnosis. The Registry is a web-based platform to distribute cross-sectional and longitudinal surveys.
- Conditions
- Neoplasms, Cancer, Caregiver
- Trial name
- CER (NCT02333604)
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Cancer Support Community, Research and Training Institute, Philadelphia
Myeloid Leukemia, Lymphoblastic Leukemia
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
The purpose of this study is to determine whether the administration of a donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR) after a T-cell depleted stem cell transplant from a related…
- Conditions
- Myeloid Leukemia, Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT00967343
- Testing
- Donor lymphocyte preparation depleted of host functional alloreactive T-cells
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 40 people
- Sponsor
- Kiadis Pharma
Pediatric ALL, Radiotherapy Side Effect
Design and Evaluation of Care Environment and Technology at Pediatric Radiotherapy
The purpose of the study is to evaluate the effect of changes in the care environment in pediatric radiotherapy. The definitions of the changes is a part of the study, and is constructed in collaboration with the institute of…
- Trial name
- DUMBO (NCT02993978)
- Volunteers
- 57 people
- Sponsor
- Umeå University
ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy
This is a pilot study utilizing Marqibo® (vincristine sulfate liposome injection) combined with dexamethasone, mitoxantrone and asparaginase (UK ALL R3) for relapsed acute lymphoblastic leukemia (ALL).
- Conditions
- ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
- Trial name
- NCT02879643
- Testing
- Marqibo
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 29 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Acute Lymphoblastic Leukemia, B Cell Lymphoma
Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies
This is the second stage of the previous anti-CD19 CAR-T therapy (NCT02965092). The study aims to evaluate the safety and efficacy of consolidative allo-HSCT following CAR-T therapy in patients with relapsed or refractory B cell…
- Trial name
- NCT03366350
- Testing
- Allogeneic hematological stem cell transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Wuhan Sian Medical Technology Co., Ltd
Covid19, Pediatric ALL
Pediatric Intensive Care and COVID-19
In this prospective longitudinal cohort the investigators reported the clinical, and biological characteristics of all critically ill patients admitted in the pediatric intensive care unit (PICU) of Bicêtre Hospital during the…
- Conditions
- Covid19, Pediatric ALL, Infection, Critical Illness
- Trial name
- CLOVIS (NCT04544878)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Bicetre Hospital
Lymphoid Leukemia, Acute Lymphoblastic Leukemia
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
This study involves Vyxeos (CPX-351), a formulation of a fixed combination of the two anti-tumor drugs, cytarabine and daunorubicin that will be given as an infusion over 90 minutes.
- Conditions
- Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
- Trial name
- NCT03575325
- Testing
- CPX-351
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lymphoma
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00217425
- Testing
- bevacizumab, cyclophosphamide, doxorubicin
- Where
- 110 sites in United States
- Volunteers
- 46 people
- Sponsor
- Eastern Cooperative Oncology Group
Acute Lymphoblastic Leukemia ALL
Study of Cell-free DNA in Children and Adolescents With Acute Lymphoblastic Leukemia
Minimal residual disease (MRD) monitoring is a key prognostic factor in pediatric acute lymphoblastic leukemia (ALL). Currently, MRD assessment relies mainly on cellular DNA obtained from bone marrow aspirates.
- Trial name
- CIRCALL (NCT07483476)
- Testing
- Biological sample collection
- Where
- 2 sites in France
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
B-cell Acute Lymphoblastic Leukemia (B-ALL)
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and efficacy of surovatamig (AZD0486) monotherapy in…
- Trial name
- SYRUS (NCT06137118)
- Testing
- Surovatamig
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 255 people
- Sponsor
- AstraZeneca
Chronic Myeloproliferative Disorders, Leukemia
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00448201
- Testing
- anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Leukemia, Acute Leukemia
Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors
The Sharing Our Strength study is being conducted to help us understand people's experiences with hematopoietic stem cell transplantation and to test a new program designed to help people recover physically and emotionally after…
- Conditions
- Leukemia, Acute Leukemia, Acute Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT00701844
- Testing
- Writing A (Experimental informative writing), Writing B (Experimental noninformative writing), Writing C (Control informative writing)
- Where
- 3 sites in United States
- Volunteers
- 315 people
- Sponsor
- University of North Carolina, Chapel Hill
Acute Lymphoblastic Leukaemia - Category
UNDERSTANDING THE T-CELL AND B-CELL RECEPTOR REPERTOIRE IN CHILDREN AND YOUNG ADULTS WITH ANTI-DRUG ANTIBODIES AGAINST PEG ASPARAGINASE
The aim of this sub study is to identify biomarkers in children and young adults with Acute Lymphoblastic Leukemia with hypersensitivity to PEG-asparaginase.
- Trial name
- NCT07499336
- Testing
- Hypersensitivity reaction to asparaginase
- Volunteers
- 45 people
- Sponsor
- Aarhus University Hospital
Relapsed or Refractory Chronic Lymphocytic Leukemia
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction
Ibrutinib, a first-in-class Bruton Tyrosine kinase (BTK) inhibitor, has become an established treatment in relapsed/refractory chronic lymphocytic leukemia (CLL).
- Trial name
- IDA53 (NCT03734198)
- Testing
- Ibrutinib, Daratumumab
- Where
- 24 sites in France
- Volunteers
- 29 people
- Sponsor
- French Innovative Leukemia Organisation